Formycon AG - Asset Resilience Ratio
Formycon AG (FYB) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Formycon AG's Asset Resilience Ratio has changed over time. Check Formycon AG (FYB) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Formycon AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Formycon AG.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.00K | 0.0% |
| Total Liquid Assets | €1.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Formycon AG maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Formycon AG Industry Peers by Asset Resilience Ratio
Compare Formycon AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Formycon AG (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Formycon AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | €1.00K ≈ $1.17K |
€739.53 Million ≈ $864.58 Million |
-5.42pp |
| 2024-12-31 | 5.42% | €41.84 Million ≈ $48.92 Million |
€771.72 Million ≈ $902.22 Million |
+2.38pp |
| 2023-12-31 | 3.04% | €27.04 Million ≈ $31.61 Million |
€890.36 Million ≈ $1.04 Billion |
-17.39pp |
| 2022-12-31 | 20.42% | €174.35 Million ≈ $203.83 Million |
€853.70 Million ≈ $998.06 Million |
-15.18pp |
| 2021-12-31 | 35.61% | €25.18 Million ≈ $29.44 Million |
€70.72 Million ≈ $82.67 Million |
-20.28pp |
| 2020-12-31 | 55.88% | €42.25 Million ≈ $49.39 Million |
€75.60 Million ≈ $88.38 Million |
+14.14pp |
| 2019-12-31 | 41.74% | €22.35 Million ≈ $26.13 Million |
€53.56 Million ≈ $62.61 Million |
+10.68pp |
| 2018-12-31 | 31.06% | €12.31 Million ≈ $14.39 Million |
€39.62 Million ≈ $46.32 Million |
-19.15pp |
| 2017-12-31 | 50.21% | €15.48 Million ≈ $18.10 Million |
€30.83 Million ≈ $36.04 Million |
-3.83pp |
| 2016-12-31 | 54.04% | €13.61 Million ≈ $15.91 Million |
€25.19 Million ≈ $29.45 Million |
-18.43pp |
| 2015-12-31 | 72.47% | €19.67 Million ≈ $23.00 Million |
€27.15 Million ≈ $31.74 Million |
+19.62pp |
| 2014-12-31 | 52.85% | €8.93 Million ≈ $10.45 Million |
€16.91 Million ≈ $19.77 Million |
-8.70pp |
| 2013-12-31 | 61.55% | €9.51 Million ≈ $11.11 Million |
€15.44 Million ≈ $18.06 Million |
+61.53pp |
| 2012-12-31 | 0.02% | €1.84K ≈ $2.15K |
€7.64 Million ≈ $8.93 Million |
-32.15pp |
| 2011-12-31 | 32.18% | €1.80 Million ≈ $2.10 Million |
€5.59 Million ≈ $6.54 Million |
-26.24pp |
| 2010-12-31 | 58.42% | €2.50 Million ≈ $2.92 Million |
€4.28 Million ≈ $5.00 Million |
-- |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more